Scott Terrillion, SEC'Y, CHIEF COMPLIANCE & G.C at Cara Therapeutics, Inc. (CARA), sold 163 shares at $4.76 ($776) on 2025-02-28, disclosed to the SEC on 2025-03-04.
Scheduled sale ($776) by SEC'Y, CHIEF COMPLIANCE & G.C under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2024-02-12 | $4K | — | Filing → |
| CARA | SELL | 2023-06-27 | $9K | — | Filing → |
| CARA | SELL | 2023-04-06 | $12K | — | Filing → |